跳至主要内容
临床试验/JPRN-UMIN000046985
JPRN-UMIN000046985已完成未知

Research of Tolvaptan prescription in SIADH patients (Observational research using DPC) - Research of Tolvaptan prescription in SIADH patients

Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department0 个研究点目标入组 2,800 人开始时间: 2022年3月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
2,800

研究概览

简要总结

As a result of examination using actual clinical data using the DPC database, half of the tolvaptan starting dose to SIADH was started from a low dose (3.75 mg), and the average administration period was 32.7 days for 3.75 mg and 33.1 days for 7.5 mg. Since mean of the serum sodium concentration at the start of the tolvaptan-administered case was 120.30 mEq / L, it is considered that the appropriate starting dose was selected for administration.

研究设计

研究类型
Observational

入排标准

年龄范围
18years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • - Patients under 18 years old

研究者

发起方
Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department

相似试验